Immunotherapy in combination with chemotherapy has become an important therapeutic treatment option in some patients with metastatic breast cancer. Which patients will benefit the most, however, remains unclear; current biomarkers such as PD-L1 that are used to predict response are mediocre at best.
https://news.vumc.org/2023/12/15/clinical-trial-shows-efficacy-for-atezolizumab-combined-with-carboplatin/
Tom Wilemon
Locked